SORT BY Relevancy
It's National Breast Cancer Awareness Month. I think it's important for everyone to know that National Breast Cancer Awareness Month was started by Zeneca Pharmaceutical (now AstraZeneca) in order to increase donations to "find a cure."
What does this really mean?
Tune in to get the scoop!
About Your Host:
Jessie Blair-Myrie, CHHC, AADP
in Self Help
Coming to you all the way from Edinburgh, Scotland. "Unleash YOUR Potential". Following on from our last show Rod will examine how you set your end goals and getting into the habit of 'Daily Qurestions' In this 60 minute show Rod and his guest Michael Beale will empower you to "Unleash YOUR Potential" and how to grab hold of it and drive forward for success
For more than 30 years, Rod has been an internationally sought-after education and management consultant and keynote speaker. His practical, real-world business experience and career has been in educational leadership, relocation consulting, and executive and leadership coaching. As a Senior Consultant and Master Executive Coach, Rod is also an Accredited ANLP Trainer - Rod specialises in Executive and Leadership Coaching.
In the past 30 years Rod has been to more than 134 different countries where he has had the opportunity to observe first hand as well as live and share multiple cultures, traditions and life styles.
Special Guest Michael Beale is one of Britains top executive coaches, his current and past clients include Accenture, Argos, AstraZeneca, Barclay’s, BT, BAE Systems, British Sugar, CSC, Canadian National Railway, Centrica, HBOS, ODPM, Oracle, Petroleum Development Oman, Roche, PM’s strategy office and main public services. Stakeholder centered coaching programmes are for more senior clients, normally last for twelve months and are based on a ‘no growth, no pay’ basis. Check more out on Michael here: http://www.execcoach.net
Learn the Rules & Regulations from a Master
Pharmaguy interviews Preeti Pinto, former Executive Director & Head of Promotional Regulatory Affairs at AstraZeneca (see Bio). We talk about the Advertising and Promotions Course that Preeti will teach at the Temple University School of Pharmacy this fall (2014).
Questions/Topics of Discussion
As a marketer, what will I learn from this course?
Is the learning just theoretical, or will the classes include hands-on learning, where students work collaboratively to solve problems?
Are there any career opportunities available for someone who takes this course?
What kind of background would I need to take this course?
Does Temple offer other related courses?
Zahir Ladhani is Vice President Smarter Workforce, IBM. Specifically, he leads the IBM Science & Consulting Group within Smarter Workforce. The goal of the Science & Consulting group is to help client's take the guesswork out of hiring, engagement, retention—and anything else that affects their workforce.
He joined Kenexa in 2010 in business development and was made President in 2011. He led the acquisition of Salary.com for Kenexa. And, with the IBM acquisition of Kenexa, along with his other responsibilities, helped aid the integration.
He joined Kenexa, an IBM company, with accounting, marketing, sales and operations experience from AstraZeneca where he was greatly involved with many major pharmaceutical launches.
Additionally, he continues to be a guest lecturer for MIT Sloan, Goldey-Beacon College and a guest speaker for IBM and World at Work, among others.
Andrew Miller, Director of Clinical Information Standards at Astrazeneca, discusses data management and the efforts to standardize ahead of chairing the Pharma IQ conference. Visit www.clinicaldataevent.com to book your place.
Recently, the Department of Labor announced that AstraZeneca will pay $250K to settle allegations of gender discrimination. The settlement decree also requires AstraZeneca to conduct a statistical analysis of base pay of sales specialists.
The statistical analysis is the key takeaway - it's better to examine your data before problems occur, rather than after.
In this installment of The Proactive Employer, we'll be discussing the AstraZeneca settlement decree, why the company should have been examining its compensation data in the first place, and how to go about a statistical analysis of compensation. We'll also discuss five key points that can keep your proactive analyses confidential, protected, and privileged.
Learn the 5 primary slogans in getting started with being fearless at work. Explore the ironies of cowardice and how to begin to tame the mind in order to establish a fearless presence.
Michael Carroll is author of Awake at Work (2004), The Mindful Leader (2007) and Fearless at Work (2012). During his 30 year business career, he has held executive positions with Shearson Lehman/American Express, Simon & Schuster and The Walt Disney Company.
Michael presently coaches and consults with such enterprises as Procter & Gamble, Google, AstraZeneca, Starbucks, RED, and National Geographic Expeditions.
AstraZeneca $520 Million Settlement Underlines the Greed Over Good Mentality Within the Pharmaceutical Industry (PI Window on Business Blog - May 2, 2010)
Antipsychotic Drug Misuse Lands Johnson & Johnson on the Wrong End of Federal Suit (PI Window on Business Blog - Mar 25, 2010)
Antipsychotic Prescriptions . . . for Children: Is the Medicaid Story Today’s Version of Go Ask Alice? (PI Window on Business Blog - Dec 13, 2009)
While the questions are too numerous and diverse to ask (although I will try), my research for this Panel Discussion re the controversy surrounding anti-psychotic drugs with Jeff Knott and Eric Wilson, leads to a serious question; At what stage does taking a productive personal inventory cross over into self-obsession or self-absorption with the intent of explaining away bad behavior through a "condition" versus taking personal ownership for one's actions?
Another question . . . have unrealistic expectations (re we have to be happy all of the time) created "conditions" that have led to the over prescribing of anti-psychotic or anti-depression drugs? And does the pharmaceutical industry recognize this trend?
While assigning blame or responsibility is a favorite pastime whenever a controversial issue crosses our collective radar, it would seem likely that this growing "problem" is in reality the convergence of the perfect storm of abdicating personal responsibility, corporate greed and a health system that is quite simply broken.
In this 60-minute segment I welcome a panel of expert authors to discuss and debate the questions surrounding the marketing, prescribing and utilization of some of the most powerful drugs available. Please note that our toll free number will be available to callers throughout the entire program.
An interview with Tony Jewell, a member of AstraZeneca's external communications team and editor of AZ Health Connections blog, about the recent #rxsave Twitter chat and plans for future pharma-hosted chats.
Dr Andrew Teasdale, Senior QA Executive at AstraZeneca, joins Pharma IQ to discuss Genotoxicity and Carcinogenicity Testing. He begins by summing up the challenges that exist with interpreting the regulatory guidelines and then discusses how people in the industry can overcome these challenges to accurately interpret the guidelines - and what changes need to be made at an industry level to overcome problems with interpreting the guidelines. The interview also covers the proposed harmonised guidelines from the ICH and whether these might solve the problems. Andrew will be presenting at the upcoming conference, Genotoxicity and Carcinogenicity Testing 2010, which will take place from 18th – 20th October in London. For anyone interested in attending, there’s still time to sign up for the conference. Further information about the agenda and speaker panel is available on our event website at www.genotoxconference.com, or alternatively you can contact our team for details on +44 (0) 207 368 9300 or email email@example.com. Andrew's new book, Genotoxic Impurities – Strategies for Identification and Control, is also due to be published late 2010/early 2011 by Wiley-Blackwell.
A conversation with Preeti Pinto, Principal at Preeti Pinto Consulting, LLC and former Executive Director & Head of Promotional Regulatory Affairs at AstraZeneca US, about the use of comparative effectiveness and health outcomes data in the support of drug promotion to physicians, payers, and consumers.
An original inThought Expert Discussion Series archive recording from 25th January, 2011. Speaking for the inThought Expert Discussion series on Personalized Antiplatelet Medicine is Paul A. Gurbel, MD, FACC joining our Snr Analyst Leon Henderson, MD to discuss products from Sanofi-Aventis, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, AstraZeneca, Portola, Novartis, Merck and Eisai. To hear the entire discussion please contact us at www.in-thought.com